anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Nuvalent · pitchdeck

Nuvalent | Investor Presentation Deck | 39 slides

39 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Nuvalent | Investor Presentation Deck | 39 slides

Nuvalent · 2023-08
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 6 slides 100% 6/6 slides 100% 6/6 slides · 27 hits
— 0/6 slides
66.7% 4/6 slides
— 0/6 slides
100% 6/6 slides 100% 6/6 slides Competitive Analysis 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides 100% 1/1 slides

Slide inventory

39
every slide · same image gating as the playbook
01
Slide 1
Features company logo, date, and a molecular structure visualization.front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a visual bracket system to connect the three pillars to the core mission statement.inspire_vision
Open slide detail
04
The slide combines a retrospective traction report with a mission/vision statement.show_traction
Open slide detail
05
Includes a grid of headshots for the leadership team and lists for board members and advisors, plus a logo-grid for prior FDA approvals.other
Open slide detail
06
Uses a Venn diagram to illustrate the intersection of Kinase Resistance and Kinase Selectivity.present_solution
Open slide detailBeat · SolutionLoop · Jobs To Be Done
07
Uses a visual process flow to contrast existing therapy failure with Nuvalent's solution.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
08
Uses a visual comparison framework to illustrate the mechanism of action and clinical benefit of selectivity.present_solution
Open slide detailLoop · Cost Of Inaction
09
present_solution
Open slide detailLoop · Cost Of Inaction
10
The slide highlights the clinical need for new therapies due to resistance mutations (G2032R) and CNS involvement.size_opportunity
Open slide detailBeat · Market SizingLoop · Cost Of Inaction
11
The table uses a green background to indicate positive results ('Yes') and white for negative results ('No').compare_peers
Open slide detailBeat · Competitive AnalysisLoop · Cost Of Inaction
12
The slide uses a human anatomy diagram to map specific TRK receptor inhibition side effects to body regions.frame_problem
Open slide detailLoop · Cost Of Inaction
13
The slide uses dot plots for IC50 data and a bar chart for tumor regression efficacy.present_solution
Open slide detail
14
The slide uses a bar chart to compare brain penetrance and a grouped bar chart to show selectivity indices across multiple drugs.present_solution
Open slide detail
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.present_framework
Open slide detail
16
The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.analyze_data
Open slide detail
17
Clinical trial baseline characteristics table.analyze_data
Open slide detail
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.analyze_data
Open slide detail
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).show_traction
Open slide detailBeat · TractionLoop · Day In Life
20
Clinical trial data presentation for NVL-520.show_traction
Open slide detailBeat · TractionLoop · Day In Life
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.show_traction
Open slide detailBeat · TractionLoop · Day In Life
22
The chart is a swimmer plot (a common clinical trial visualization).show_traction
Open slide detailBeat · TractionLoop · Day In Life
23
Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.show_traction
Open slide detailBeat · TractionLoop · Day In Life
24
Includes patient case study images and clinical trial metrics.show_traction
Open slide detailBeat · TractionLoop · Day In Life
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.illustrate_case
Open slide detail
26
Slide 26 of a clinical presentation.summarize
Open slide detail
27
The slide uses a list of icons to represent key features of the drug candidate.present_solution
Open slide detail
28
The table highlights the progression of resistance mutations and the increasing prevalence of CNS disease as patients move through lines of therapy.size_opportunity
Open slide detail
29
The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.compare_peers
Open slide detail
30
The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.present_solution
Open slide detail
31
The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.show_traction
Open slide detail
32
The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.analyze_data
Open slide detail
33
The slide outlines the key therapeutic advantages of the drug candidate NVL-330.present_solution
Open slide detail
34
Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.present_solution
Open slide detail
35
transition
Open slide detail
36
The slide uses a cascading hexagonal process flow to illustrate the methodology.present_framework
Open slide detail
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.plan_implementation
Open slide detail
38
Includes a molecular structure visualization.present_solution
Open slide detail
39
front_matter
Open slide detail